In amygdala-kindled rats, single-dose administration of primidone did not reduced seizure activity 2 h after i.p. injection, i.e. when plasma levels of the drug were highest, but significant anticonvulsant effects were found 24 h after administration, when the drug was almost completely eliminated. During chronic treatment with primidone, marked anticonvulsant efficacy was determined after 3-15 days of three times daily treatment with 50 mg/kg i.p., indicating that this effect was due to the accumulation of metabolites, especially phenobarbital. Maximum anticonvulsant activity attained during chronic primidone medication was almost equal to that found during chronic treatment of kindled rats with phenobarbital, 30 mg/kg once daily. However, drug plasma level determinations during both treatments showed that on days when both treatments were about equieffective, levels of metabolically derived phenobarbital in the primidone group were significantly lower than levels in rats treated with phenobarbital alone, thus indicating that primidone potentiated the anticonvulsant effect of metabolically derived phenobarbital. Additional evidence for potentiation of the anticonvulsant effect of phenobarbital by primidone was found in single dose experiments with combined injection of both drugs, whereas side-effects, such as ataxia and muscle relaxation, induced by phenobarbital were not increased by combined treatment with primidone. Accordingly, side-effects occurring during chronic primidone treatment were less pronounced than side-effects found during chronic phenobarbital medication. In both treatment groups, tolerance to the anticonvulsant effect developed during the 2nd week of administration, while attenuation of side-effects took place already in the first week. Following cessation of treatment, signs of physical dependence, such as withdrawal hyperexcitability and weight loss, were observed. The data indicate that, at least in kindled rats, the anticonvulsant activity of primidone during chronic treatment is due to the combined and possibly synergistic actions of primidone and metabolically derived phenobarbital.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0014-2999(89)90294-x | DOI Listing |
Introduction: Chronic ischemic heart failure is a major global health issue despite advancements in therapy. Stem cell (SC) therapy has emerged as a potential treatment, but its effectiveness remains uncertain. This study aimed to systematically review and meta-analyze the current evidence on SC therapy's efficacy.
View Article and Find Full Text PDFJ Glob Health
December 2024
Department of Anesthesiology, Critical Care and Pain Medicine, UTHealth, Houston, Texas, USA.
Background: Previous studies have shown that hypertonic saline nasal irrigation and gargling reduced the duration of symptoms in upper respiratory infections caused by coronavirus. This study aims to investigate the effects of two saline regimens on symptoms associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Methods: Between 2020 and 2022, individuals aged 18-65 years who tested positive for SARS-CoV-2 infection via polymerase chain reaction (PCR) were randomly assigned to either low- or high-saline regimens for 14 days.
Cureus
December 2024
Pulmonology/Critical Care, University of Kansas School of Medicine, Wichita, USA.
Empyema, a type of pleural effusion characterized by pus accumulation in the pleural space, is most often caused by bacterial infections, typically as a complication of pneumonia. This case report presents a 70-year-old man with chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, and chronic bilateral hydropneumothoraces, who developed pyopneumothorax due to dual infections with and . The patient presented with worsening dyspnea, hypoxemia, and respiratory acidosis, requiring hospitalization and chest tube thoracostomy.
View Article and Find Full Text PDFCureus
December 2024
Family Medicine, Augusta University Medical College of Georgia, Chatsworth, USA.
Hairy cell leukemia (HCL) is a rare, chronic B-cell malignancy with an indolent course that typically responds well to purine nucleoside analogs, such as cladribine. We present the case of a 74-year-old woman with nearly three decades of recurrent HCL, marked by multiple relapses and significant toxicities to various treatments, including purine analogs, BRAF inhibitors, BTK inhibitors, a cytoreductive agent, and the monoclonal antibody rituximab. Despite severe allergic reactions and intolerances to standard therapies, the patient achieved multiple remissions.
View Article and Find Full Text PDFCureus
December 2024
Ophthalmology, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, TUR.
Purpose This study evaluated the efficacy of oral melatonin therapy for visual acuity and retinal and choroidal structures in patients with chronic central serous chorioretinopathy (CSCR). Methods Fourteen patients with CSCR were included; eight received oral melatonin (3 mg nightly), and six formed the control group. Best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and choroidal vascularity index (CVI) were assessed at baseline and after one month.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!